share_log

中國生物製藥：自願公告 - 「鹽酸安羅替尼膠囊」、「TQB2916（CD40激動劑）」共5項研究數據將在2024 AACR公佈

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF 5 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES" AND "TQB2916 (CD40 AGONIST)" WILL BE PRESENTED AT 2024 AACR

香港交易所 ·  Mar 11 06:56
Summary by Moomoo AI
中國生物製藥有限公司宣佈，旗下正大天晴藥業集團股份有限公司開發的兩款創新藥「鹽酸安羅替尼膠囊」及「TQB2916（CD40激動劑）」將於2024年在美國癌症協會年會（AACR）公佈五項研究成果。這些研究涵蓋了消化道腫瘤、小細胞肺癌、晚期惡性腫瘤、甲狀腺髓樣癌及晚期卵巢癌等多種癌症。鹽酸安羅替尼膠囊是一款口服新型小分子多靶點受體酪氨酸激酶抑制劑，已獲批五個適應症，並有兩個新適應症正在申請中。TQB2916作為一種全人源IgG2單抗，主要通過激活抗原提呈細胞以發揮腫瘤抑製作用，目前全球尚無CD40激動劑獲批上市。中國生物製藥有限公司董事會由七位執行董事及五位獨立非執行董事組成。
中國生物製藥有限公司宣佈，旗下正大天晴藥業集團股份有限公司開發的兩款創新藥「鹽酸安羅替尼膠囊」及「TQB2916（CD40激動劑）」將於2024年在美國癌症協會年會（AACR）公佈五項研究成果。這些研究涵蓋了消化道腫瘤、小細胞肺癌、晚期惡性腫瘤、甲狀腺髓樣癌及晚期卵巢癌等多種癌症。鹽酸安羅替尼膠囊是一款口服新型小分子多靶點受體酪氨酸激酶抑制劑，已獲批五個適應症，並有兩個新適應症正在申請中。TQB2916作為一種全人源IgG2單抗，主要通過激活抗原提呈細胞以發揮腫瘤抑製作用，目前全球尚無CD40激動劑獲批上市。中國生物製藥有限公司董事會由七位執行董事及五位獨立非執行董事組成。
CHINA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT TWO INNOVATIVE DRUGS “ALOTINIC HYDROCHLORIDE CAPSULE” AND “TQB2916 (CD40 STIMULANT)” DEVELOPED BY CHENGDAI TIANCHING PHARMACEUTICAL GROUP CO., LTD., WILL BE ANNOUNCED AT THE ANNUAL MEETING OF THE AMERICAN CANCER SOCIETY (AACR) IN 2024. These studies covered a variety of cancers including gastrointestinal tumors, small cell lung cancer, late-stage malignant tumors, thyroid medullary cancer, and late ovarian cancer. Alotinic hydrochloride capsule is an oral novel small molecule multi-target receptor tyrosine kinase inhibitor that has been approved for five indications and two new indications are in application. TQB2916 is an all-human IgG2 monoantibody that acts primarily by activating antigen-presenting cells to act as tumor suppressors. No CD40 activator has been marketed globally. The Board of Directors of China Biopharmaceuticals Limited consists of seven executive directors and five independent non-executive directors.
CHINA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT TWO INNOVATIVE DRUGS “ALOTINIC HYDROCHLORIDE CAPSULE” AND “TQB2916 (CD40 STIMULANT)” DEVELOPED BY CHENGDAI TIANCHING PHARMACEUTICAL GROUP CO., LTD., WILL BE ANNOUNCED AT THE ANNUAL MEETING OF THE AMERICAN CANCER SOCIETY (AACR) IN 2024. These studies covered a variety of cancers including gastrointestinal tumors, small cell lung cancer, late-stage malignant tumors, thyroid medullary cancer, and late ovarian cancer. Alotinic hydrochloride capsule is an oral novel small molecule multi-target receptor tyrosine kinase inhibitor that has been approved for five indications and two new indications are in application. TQB2916 is an all-human IgG2 monoantibody that acts primarily by activating antigen-presenting cells to act as tumor suppressors. No CD40 activator has been marketed globally. The Board of Directors of China Biopharmaceuticals Limited consists of seven executive directors and five independent non-executive directors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more